<?xml version="1.0" encoding="UTF-8"?>
<p>Several attempts are being made to use IVIg and monoclonal antibodies in COVID-19. However, both approaches are expensive. Additionally, SARS-CoV-2 is capable of mutating, further challenging the use of specific antibody therapies.</p>
